{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:33:08Z","timestamp":1793745188206,"version":"4.6.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several studies have evaluated immune checkpoint inhibitors (ICIs) for metastatic uveal melanoma; however, the efficacy of ICIs in the previous studies varied greatly. In this systematic review, we searched for prospective or retrospective studies on single or dual-ICIs for metastatic uveal melanoma treatment. A random-effect model meta-analysis with generic inverse-variance was conducted, and 36 articles representing 41 cohorts of 1414 patients with metastatic uveal melanoma were included. The pooled outcomes were as follows: objective response rate (ORR) was 5.6% (95% confidence interval [95%CI] 3.7\u20137.5%; I<jats:sup>2<\/jats:sup>, 36%), disease control rate (DCR) was 32.5% (95% CI 27.2\u201337.7%; I<jats:sup>2<\/jats:sup>, 73%), median progression-free survival was 2.8\u00a0months (95% CI 2.7\u20132.9\u00a0months; I<jats:sup>2<\/jats:sup>, 26%), and median overall survival (OS) was 11.2\u00a0months (95% CI 9.6\u201313.2\u00a0months; I<jats:sup>2<\/jats:sup>, 74%). Compared to single-agent ICI, dual ICI led to better ORR (single-agent: 3.4% [95% CI 1.8\u20135.1]; dual-agent: 12.4% [95% CI 8.0\u201316.9]; P\u2009&lt;\u20090.001), DCR (single-agent: 29.3%, [95% CI 23.4\u201335.2]; dual-agent: 44.3% [95% CI 31.7\u201356.8]; P\u2009=\u20090.03), and OS (single-agent: 9.8\u00a0months [95% CI 8.0\u201312.2]; dual-agent: 16.3\u00a0months [95% CI 13.5\u201319.7]; P\u2009&lt;\u20090.001). Our analysis provided treatment outcomes as described above. Dual-ICIs appear better than single-agent ICIs for the treatment of metastatic uveal melanoma.<\/jats:p>","DOI":"10.1038\/s41598-024-55675-5","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T16:02:21Z","timestamp":1712160141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis"],"prefix":"10.1038","volume":"14","author":[{"given":"Kayoko","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Mizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Mizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Horita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"55675_CR1","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1101\/gad.296962.117","volume":"31","author":"C Pandiani","year":"2017","unstructured":"Pandiani, C., B\u00e9ranger, G. E., Leclerc, J., Ballotti, R. & Bertolotto, C. Focus on cutaneous and uveal melanoma specificities. Genes Dev. 31, 724\u2013743. https:\/\/doi.org\/10.1101\/gad.296962.117 (2017).","journal-title":"Genes Dev."},{"key":"55675_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000513336","volume":"7","author":"M Orloff","year":"2021","unstructured":"Orloff, M. Clinical trials in metastatic uveal melanoma: Immunotherapy. Ocul. Oncol. Pathol. 7, 168\u2013176. https:\/\/doi.org\/10.1159\/000513336 (2021).","journal-title":"Ocul. Oncol. Pathol."},{"key":"55675_CR3","doi-asserted-by":"publisher","first-page":"101041","DOI":"10.1016\/j.preteyeres.2022.101041","volume":"90","author":"ES Rantala","year":"2022","unstructured":"Rantala, E. S., Hernberg, M. M., Piperno-Neumann, S., Grossniklaus, H. E. & Kivel\u00e4, T. T. Metastatic uveal melanoma: The final frontier. Prog. Retin. Eye Res. 90, 101041. https:\/\/doi.org\/10.1016\/j.preteyeres.2022.101041 (2022).","journal-title":"Prog. Retin. Eye Res."},{"key":"55675_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070971","author":"BE Damato","year":"2019","unstructured":"Damato, B. E., Dukes, J., Goodall, H. & Carvajal, R. D. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers https:\/\/doi.org\/10.3390\/cancers11070971 (2019).","journal-title":"Cancers"},{"key":"55675_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","volume":"29","author":"ES Rantala","year":"2019","unstructured":"Rantala, E. S., Hernberg, M. & Kivela, T. T. Overall survival after treatment for metastatic uveal melanoma: A systematic review and meta-analysis. Melanoma Res. 29, 561\u2013568. https:\/\/doi.org\/10.1097\/CMR.0000000000000575 (2019).","journal-title":"Melanoma Res."},{"key":"55675_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21030879","author":"A Wessely","year":"2020","unstructured":"Wessely, A. et al. The Role of Immune Checkpoint Blockade in Uveal Melanoma. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21030879 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"55675_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466 (2010).","journal-title":"N. Engl. J. Med."},{"key":"55675_CR8","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1167\/iovs.02-1329","volume":"44","author":"Y Cohen","year":"2003","unstructured":"Cohen, Y. et al. Lack of BRAF mutation in primary uveal melanoma. Investig. Ophthalmol. Vis. Sci. 44, 2876\u20132878. https:\/\/doi.org\/10.1167\/iovs.02-1329 (2003).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"55675_CR9","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/sj.bjc.6600919","volume":"88","author":"SC Edmunds","year":"2003","unstructured":"Edmunds, S. C. et al. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br. J. Cancer 88, 1403\u20131405. https:\/\/doi.org\/10.1038\/sj.bjc.6600919 (2003).","journal-title":"Br. J. Cancer"},{"key":"55675_CR10","first-page":"5712","volume":"63","author":"D Rimoldi","year":"2003","unstructured":"Rimoldi, D. et al. Lack of BRAF mutations in uveal melanoma. Cancer Res. 63, 5712\u20135715 (2003).","journal-title":"Cancer Res."},{"key":"55675_CR11","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196\u20131206. https:\/\/doi.org\/10.1056\/NEJMoa2103485 (2021).","journal-title":"N. Engl. J. Med."},{"key":"55675_CR12","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126 (2018).","journal-title":"N. Engl. J. Med."},{"key":"55675_CR13","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1801946 (2018).","journal-title":"N. Engl. J. Med."},{"key":"55675_CR14","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1200\/jco.2017.76.6212","volume":"36","author":"YY Janjigian","year":"2018","unstructured":"Janjigian, Y. Y. et al. CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J. Clin. Oncol. 36, 2836\u20132844. https:\/\/doi.org\/10.1200\/jco.2017.76.6212 (2018).","journal-title":"J. Clin. Oncol."},{"key":"55675_CR15","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/jco.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman, M. J. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36, 773\u2013779. https:\/\/doi.org\/10.1200\/jco.2017.76.9901 (2018).","journal-title":"J. Clin. Oncol."},{"key":"55675_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/s0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375\u2013386. https:\/\/doi.org\/10.1016\/s0140-6736(20)32714-8 (2021).","journal-title":"Lancet"},{"key":"55675_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejca.2021.01.031","volume":"147","author":"T Fukumoto","year":"2021","unstructured":"Fukumoto, T. & Horita, N. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma. Eur. J. Cancer 147, 140\u2013141. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.031 (2021).","journal-title":"Eur. J. Cancer"},{"key":"55675_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. cancer 45, 228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026 (2009).","journal-title":"Eur. J. cancer"},{"key":"55675_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25, 603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z (2010).","journal-title":"Eur. J. Epidemiol."},{"key":"55675_CR20","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 http:\/\/handbook.cochrane.org\/front_page.htm (Accessed February 2022) (2022)."},{"key":"55675_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","volume":"22","author":"EB Wilson","year":"1927","unstructured":"Wilson, E. B. Probable inference, the law of succession, and statistical inference. J. Am. Stat. Assoc. 22, 209\u2013212. https:\/\/doi.org\/10.1080\/01621459.1927.10502953 (1927).","journal-title":"J. Am. Stat. Assoc."},{"key":"55675_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/EDE.0b013e318282a66c","volume":"24","author":"J Zang","year":"2013","unstructured":"Zang, J., Xiang, C. & He, J. Synthesis of median survival time in meta-analysis. Epidemiology 24, 337\u2013338. https:\/\/doi.org\/10.1097\/EDE.0b013e318282a66c (2013).","journal-title":"Epidemiology"},{"key":"55675_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ 327, 557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557 (2003).","journal-title":"BMJ"},{"key":"55675_CR24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/cmr.0000000000000185","volume":"25","author":"SS Ahmad","year":"2015","unstructured":"Ahmad, S. S. et al. Ipilimumab in the real world: The UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Res. 25, 432\u2013442. https:\/\/doi.org\/10.1097\/cmr.0000000000000185 (2015).","journal-title":"Melanoma Res."},{"key":"55675_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5694\/mja13.10448","volume":"201","author":"M Alexander","year":"2014","unstructured":"Alexander, M., Mellor, J. D., McArthur, G. & Kee, D. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. Med. J. Aust. 201, 49\u201353. https:\/\/doi.org\/10.5694\/mja13.10448 (2014).","journal-title":"Med. J. Aust."},{"key":"55675_CR26","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","volume":"122","author":"AP Algazi","year":"2016","unstructured":"Algazi, A. P. et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 122, 3344\u20133353. https:\/\/doi.org\/10.1002\/cncr.30258 (2016).","journal-title":"Cancer"},{"key":"55675_CR27","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/cam4.887","volume":"6","author":"C Bender","year":"2017","unstructured":"Bender, C., Enk, A., Gutzmer, R. & Hassel, J. C. Anti-PD-1 antibodies in metastatic uveal melanoma: A treatment option?. Cancer Med. 6, 1581\u20131586. https:\/\/doi.org\/10.1002\/cam4.887 (2017).","journal-title":"Cancer Med."},{"key":"55675_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101489","author":"KF Bol","year":"2019","unstructured":"Bol, K. F. et al. Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma. Cancers https:\/\/doi.org\/10.3390\/cancers11101489 (2019).","journal-title":"Cancers"},{"key":"55675_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00262-011-1089-0","volume":"61","author":"R Danielli","year":"2012","unstructured":"Danielli, R. et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: Safety and clinical efficacy. Cancer Immunol. Immunother. 61, 41\u201348. https:\/\/doi.org\/10.1007\/s00262-011-1089-0 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"55675_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2017.05.038","volume":"82","author":"MV Heppt","year":"2017","unstructured":"Heppt, M. V. et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1\/cytotoxic T-lymphocyte antigen-4 inhibition. Eur. J. Cancer 82, 56\u201365. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.038 (2017).","journal-title":"Eur. J. Cancer"},{"key":"55675_CR31","doi-asserted-by":"publisher","first-page":"203636132097198","DOI":"10.1177\/2036361320971983","volume":"12","author":"YJL Jansen","year":"2020","unstructured":"Jansen, Y. J. L., Seremet, T. & Neyns, B. Pembrolizumab for the treatment of uveal melanoma: A case series. Rare tumors 12, 2036361320971983. https:\/\/doi.org\/10.1177\/2036361320971983 (2020).","journal-title":"Rare tumors"},{"key":"55675_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.6004\/jnccn.2018.7070","volume":"17","author":"DB Johnson","year":"2019","unstructured":"Johnson, D. B. et al. Response to Anti-PD-1 in uveal melanoma without high-volume liver metastasis. J. Natl. Compr. Cancer Netw. 17, 114\u2013117. https:\/\/doi.org\/10.6004\/jnccn.2018.7070 (2019).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"55675_CR33","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/cmr.0000000000000175","volume":"25","author":"AM Joshua","year":"2015","unstructured":"Joshua, A. M. et al. A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Melanoma Res. 25, 342\u2013347. https:\/\/doi.org\/10.1097\/cmr.0000000000000175 (2015).","journal-title":"Melanoma Res."},{"key":"55675_CR34","doi-asserted-by":"publisher","first-page":"e1143997","DOI":"10.1080\/2162402x.2016.1143997","volume":"5","author":"I Karydis","year":"2016","unstructured":"Karydis, I. et al. Clinical activity and safety of pembrolizumab in ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology 5, e1143997. https:\/\/doi.org\/10.1080\/2162402x.2016.1143997 (2016).","journal-title":"Oncoimmunology"},{"key":"55675_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40425-018-0459-y","volume":"7","author":"U Keilholz","year":"2019","unstructured":"Keilholz, U. et al. Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN solid tumor trial. J. Immunother. Cancer 7, 12. https:\/\/doi.org\/10.1186\/s40425-018-0459-y (2019).","journal-title":"J. Immunother. Cancer"},{"key":"55675_CR36","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3109\/0284186x.2013.786839","volume":"52","author":"S Kelderman","year":"2013","unstructured":"Kelderman, S. et al. Ipilimumab in pretreated metastastic uveal melanoma patients. results of the dutch working group on immunotherapy of oncology (WIN-O). Acta Oncologica 52, 1786\u20131788. https:\/\/doi.org\/10.3109\/0284186x.2013.786839 (2013).","journal-title":"Acta Oncologica"},{"key":"55675_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143640","author":"D Kelly","year":"2021","unstructured":"Kelly, D. et al. Development of a metastatic uveal melanoma prognostic score (MUMPS) for use in patients receiving immune checkpoint inhibitors. Cancers https:\/\/doi.org\/10.3390\/cancers13143640 (2021).","journal-title":"Cancers"},{"key":"55675_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/CMR.0b013e32835b554f","volume":"23","author":"MA Khattak","year":"2013","unstructured":"Khattak, M. A., Fisher, R., Hughes, P., Gore, M. & Larkin, J. Ipilimumab activity in advanced uveal melanoma. Melanoma Res. 23, 79\u201381. https:\/\/doi.org\/10.1097\/CMR.0b013e32835b554f (2013).","journal-title":"Melanoma Res."},{"key":"55675_CR39","doi-asserted-by":"publisher","first-page":"28903","DOI":"10.18632\/oncotarget.25627","volume":"9","author":"MC Kirchberger","year":"2018","unstructured":"Kirchberger, M. C., Moreira, A., Erdmann, M., Schuler, G. & Heinzerling, L. Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients. Oncotarget 9, 28903\u201328909. https:\/\/doi.org\/10.18632\/oncotarget.25627 (2018).","journal-title":"Oncotarget"},{"key":"55675_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000341","author":"ND Klemen","year":"2020","unstructured":"Klemen, N. D. et al. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2019-000341 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"55675_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030518","author":"EAT Koch","year":"2022","unstructured":"Koch, E. A. T. et al. Immune checkpoint blockade for metastatic uveal melanoma: Re-induction following resistance or toxicity. Cancers https:\/\/doi.org\/10.3390\/cancers14030518 (2022).","journal-title":"Cancers"},{"key":"55675_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/0284186x.2016.1260773","volume":"56","author":"MK van der Kooij","year":"2017","unstructured":"van der Kooij, M. K. et al. Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands. Acta Oncol. 56, 101\u2013103. https:\/\/doi.org\/10.1080\/0284186x.2016.1260773 (2017).","journal-title":"Acta Oncol."},{"key":"55675_CR43","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/cmr.0000000000000242","volume":"26","author":"LA Kottschade","year":"2016","unstructured":"Kottschade, L. A. et al. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res. 26, 300\u2013303. https:\/\/doi.org\/10.1097\/cmr.0000000000000242 (2016).","journal-title":"Melanoma Res."},{"key":"55675_CR44","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1002\/cncr.28282","volume":"119","author":"JJ Luke","year":"2013","unstructured":"Luke, J. J. et al. Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the dana-farber cancer institute, massachusetts general hospital, memorial sloan-kettering cancer center, and university hospital of lausanne experience. Cancer 119, 3687\u20133695. https:\/\/doi.org\/10.1002\/cncr.28282 (2013).","journal-title":"Cancer"},{"key":"55675_CR45","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1093\/annonc\/mdt376","volume":"24","author":"M Maio","year":"2013","unstructured":"Maio, M. et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann.Oncol. 24, 2911\u20132915. https:\/\/doi.org\/10.1093\/annonc\/mdt376 (2013).","journal-title":"Ann.Oncol."},{"key":"55675_CR46","doi-asserted-by":"publisher","first-page":"1908065","DOI":"10.1155\/2018\/1908065","volume":"2018","author":"C Mignard","year":"2018","unstructured":"Mignard, C. et al. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma. J. Oncol. 2018, 1908065. https:\/\/doi.org\/10.1155\/2018\/1908065 (2018).","journal-title":"J. Oncol."},{"key":"55675_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/cmr.0000000000000125","volume":"25","author":"JC Moser","year":"2015","unstructured":"Moser, J. C. et al. The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma. Melanoma Res. 25, 59\u201363. https:\/\/doi.org\/10.1097\/cmr.0000000000000125 (2015).","journal-title":"Melanoma Res."},{"key":"55675_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000331","author":"YG Najjar","year":"2020","unstructured":"Najjar, Y. G. et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: A multicenter, retrospective study. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2019-000331 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"55675_CR49","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/cmr.0000000000000617","volume":"30","author":"K Namikawa","year":"2020","unstructured":"Namikawa, K. et al. Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: A single-institution retrospective study. Melanoma Res. 30, 76\u201384. https:\/\/doi.org\/10.1097\/cmr.0000000000000617 (2020).","journal-title":"Melanoma Res."},{"key":"55675_CR50","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2019.07.010","volume":"119","author":"P Nathan","year":"2019","unstructured":"Nathan, P. et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). Eur. J. Cancer 119, 168\u2013178. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.010 (2019).","journal-title":"Eur. J. Cancer"},{"key":"55675_CR51","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/jco.20.00605","volume":"39","author":"MS Pelster","year":"2021","unstructured":"Pelster, M. S. et al. Nivolumab and ipilimumab in metastatic uveal melanoma: Results from a single-arm phase II study. J. Clin. Oncol. 39, 599\u2013607. https:\/\/doi.org\/10.1200\/jco.20.00605 (2021).","journal-title":"J. Clin. Oncol."},{"key":"55675_CR52","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/jco.20.00550","volume":"39","author":"JM Piulats","year":"2021","unstructured":"Piulats, J. M. et al. Nivolumab plus ipilimumab for treatment-na\u00efve metastatic uveal melanoma: An open-label, multicenter, phase II trial by the spanish multidisciplinary melanoma group (GEM-1402). J. Clin. Oncol. 39, 586\u2013598. https:\/\/doi.org\/10.1200\/jco.20.00550 (2021).","journal-title":"J. Clin. Oncol."},{"key":"55675_CR53","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00262-019-02352-6","volume":"68","author":"E Rossi","year":"2019","unstructured":"Rossi, E. et al. Pembrolizumab as first-line treatment for metastatic uveal melanoma. Cancer Immunol. Immunother. 68, 1179\u20131185. https:\/\/doi.org\/10.1007\/s00262-019-02352-6 (2019).","journal-title":"Cancer Immunol. Immunother."},{"key":"55675_CR54","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1002\/cam4.3784","volume":"10","author":"MS Sander","year":"2021","unstructured":"Sander, M. S. et al. Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors. Cancer Med. 10, 2618\u20132626. https:\/\/doi.org\/10.1002\/cam4.3784 (2021).","journal-title":"Cancer Med."},{"key":"55675_CR55","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/cmr.0000000000000744","volume":"31","author":"SY Tacar","year":"2021","unstructured":"Tacar, S. Y. et al. Nivolumab for metastatic uveal melanoma: A multicenter, retrospective study. Melanoma Res. 31, 449\u2013455. https:\/\/doi.org\/10.1097\/cmr.0000000000000744 (2021).","journal-title":"Melanoma Res."},{"key":"55675_CR56","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5114\/wo.2013.35785","volume":"17","author":"K Wiater","year":"2013","unstructured":"Wiater, K. et al. Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: A retrospective multicenter analysis. Contemp. oncol. 17, 257\u2013262. https:\/\/doi.org\/10.5114\/wo.2013.35785 (2013).","journal-title":"Contemp. oncol."},{"key":"55675_CR57","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000495113","volume":"5","author":"LT Xu","year":"2019","unstructured":"Xu, L. T. et al. Uveal melanoma metastatic to the liver: Treatment trends and outcomes. Ocul. oncol. Pathol. 5, 323\u2013332. https:\/\/doi.org\/10.1159\/000495113 (2019).","journal-title":"Ocul. oncol. Pathol."},{"key":"55675_CR58","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/1078155219840796","volume":"26","author":"Turkish Oncology Group study","year":"2020","unstructured":"Turkish Oncology Group study. Arzu Ya\u015far, H. et al. Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab. J. Oncol. Pharm. Pract. 26, 267\u2013272. https:\/\/doi.org\/10.1177\/1078155219840796 (2020).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"55675_CR59","doi-asserted-by":"publisher","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","volume":"10","author":"L Zimmer","year":"2015","unstructured":"Zimmer, L. et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-na\u00efve patients with metastatic uveal melanoma. PloS ONE 10, e0118564. https:\/\/doi.org\/10.1371\/journal.pone.0118564 (2015).","journal-title":"PloS ONE"},{"key":"55675_CR60","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.7150\/jca.72210","volume":"13","author":"J Pradeep","year":"2022","unstructured":"Pradeep, J., Win, T. T., Aye, S. N. & Sreeramareddy, C. T. Efficacy and safety of immune checkpoint inhibitors for advanced malignant melanoma: A meta-analysis on monotherapy vs combination therapy. J. Cancer 13, 3091\u20133102. https:\/\/doi.org\/10.7150\/jca.72210 (2022).","journal-title":"J. Cancer"},{"key":"55675_CR61","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.4103\/jcrt.jcrt_1669_21","volume":"17","author":"Y Zhu","year":"2021","unstructured":"Zhu, Y. et al. The efficacy and safety of combined ipilimumab and nivolumab versus ipilimumab in patients with Stage III\/IV unresectable melanoma: A systematic review and meta-analysis. J. Cancer Res. Ther. 17, 1679\u20131688. https:\/\/doi.org\/10.4103\/jcrt.jcrt_1669_21 (2021).","journal-title":"J. Cancer Res. Ther."},{"key":"55675_CR62","doi-asserted-by":"publisher","first-page":"102543","DOI":"10.1016\/j.ctrv.2023.102543","volume":"115","author":"A Petzold","year":"2023","unstructured":"Petzold, A. et al. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment. Cancer Ttreat. Rev. 115, 102543. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102543 (2023).","journal-title":"Cancer Ttreat. Rev."},{"key":"55675_CR63","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fimmu.2019.00453","volume":"10","author":"DO Khair","year":"2019","unstructured":"Khair, D. O. et al. Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma. Front. Immunol. 10, 453. https:\/\/doi.org\/10.3389\/fimmu.2019.00453 (2019).","journal-title":"Front. Immunol."},{"key":"55675_CR64","doi-asserted-by":"publisher","first-page":"175883592311984","DOI":"10.1177\/17588359231198453","volume":"15","author":"H Matsumoto","year":"2023","unstructured":"Matsumoto, H. et al. Adverse events induced by durvalumab and tremelimumab combination regimens: A systematic review and meta-analysis. Ther. Adv. Med. Oncol. 15, 17588359231198452. https:\/\/doi.org\/10.1177\/17588359231198453 (2023).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"55675_CR65","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211058393","author":"K Somekawa","year":"2022","unstructured":"Somekawa, K. et al. Adverse events induced by nivolumab and ipilimumab combination regimens. Ther. Adv. Med. Oncol. https:\/\/doi.org\/10.1177\/17588359211058393 (2022).","journal-title":"Ther. Adv. Med. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55675-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55675-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55675-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T16:12:34Z","timestamp":1712160754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55675-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["55675"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-55675-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"assertion":[{"value":"23 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7887"}}